


(PROGRAM) VACCINES SUMMIT BOSTON 2023





www.biogatesc.com/events/va-cc-in-e/ Boston Marriott Newton Hotel, Newton, MA, USA





ADVISORY BOARD MEMBERS



LUIS RÍOS NOGALES GARCES

EXECUTIVE VP & CDO ILIAD BIOTECNOLOGIES, USA





SABINE HAUCK EVP CORPORATE DEVELOPMENT LEUKOCARE AG, GERMANY



DON J. DIAMOND

PROFESSOR DEPARTMENT OF HEMATOLOGY & HEMATOPOIETIC CELL TRANSPLANTATION CITY OF HOPE, USA

WILLIAM R. JACOBS JR.

LEO & JULIA FORCHHEIMER CHAIR MICROBIOLOGY & IMMUNOLOGY ALBERT EINSTEIN COLLEGE OF MEDICINE, USA

ORGANIZING COMMITTEE MEMBERS



SACHIN SRAVAN

FOUNDER & CEO BIOGATE SCIENTIFIC CENTER

PRIYANKA M

PROJECT DIRECTOR - CONFERENCES BIOGATE SCIENTIFIC CENTER



WELCOME MESSAGE



DON J. DIAMOND

PROFESSOR DEPARTMENT OF HEMATOLOGY & HEMATOPOIETIC CELL TRANSPLANTATION CITY OF HOPE, USA

I want to personally welcome all of the delegates and speakers to the hub, as fellow Bostonians refer to this vibrant and pulsating city. This excellent locale for a conference brings together the very best talent in the vaccine field. While the conference site might be in Waltham, everything in the metro area is influenced by the dynamic commercial and academic environment in the hub locale. We have assembled a topnotch group of speakers and advisors to guide the content and direction of this meeting. The choice of topics spans the gamut of cutting edge science, commercial development, and clinical application of vaccines for a whole range of diseases in the global sense. Diseases of the developing world, the tropical climates, Africa and the middle east, and the western world are all covered by individual presentations by noted authorities in each of these disciplines. The meeting will cover both delivery mechanisms as well as individual vaccine examples for major disease groups plaguing our planet. Speakers come from national health agencies from Europe and the USA, large pharma represented by some of the most prestigious names, small biotechs and startups, and faculty from European and American academia. One could not ask for a more diverse group of speakers who will enlighten us on a range of topics than span the vaccine universe. I encourage anyone who is devoted to this discipline and its many allied academic and commercial applications to register to participate as this will be the highlight of the many conferences that will bombard you to attend. This is a "not to be missed" gathering that will enrich all of us, so

when we return to our workplaces, we will have learned something new and cutting edge to incorporate into our own work and discoveries.

It is my great pleasure to welcome all participants to the Vaccine Summit Boston 2023. I am excited to meet colleagues from the vaccine world again on-site at this vibrant biotech community in Massachusetts. After a lean period, distinguished presenters from the USA and Europe will eventually regather in Boston to share their knowledge and experience with the vaccine community. An opportunity, that provides scientific insights combined with networking opportunities across all areas. It is this scientific exchange that helps us to develop and excel in our field. With the booster of recent years, the vaccine field emerged into new areas. The Vaccine Summit Boston 2023 will present new applications of the RNA vaccine technology for prophylactic vaccines. We will also hear how vaccines can benefit from cell therapies. I am particularly excited that this conference will also delve into therapeutic vaccination concepts, aiming to treat infectious diseases or cancer. I am looking forward to fruitful interactions among participants and to an inspiring conference.



SABINE HAUCK

EXECUTIVE VICE-PRESIDENT CORPORATE DEVELOPMENT LEUKOCARE AG, GERMANY



SUPPORTERS

-0**:-X-**:0

GOLD SPONSOR SILVER SPONSOR BRONZE SPONSOR







COLLABORATOR SCHOLARLY SERVICES PARTNER





FOR SPONSORSHIP AND EXHIBITION OPPORTUNITIES, PLEASE CONTACT: SACHIN SRAVAN <u>Email: sachin@bsc.events</u>

FOR SPEAKING OPPORTUNITIES AND DELEGATE SERVICES, PLEASE CONTACT: PRIVANKA M Email: priyanka.m@bsc.events

TARGET AUDIENCE

- C-LEVEL EXECUTIVES
- SENIOR SCIENTISTS
- DECISION MAKERS
- PRESIDENTS, VPS & SVPS
- DRUG DEVELOPERS
- ACADEMICIANS
- MANUFACTURERS
- RESEARCHERS & DEVELOPERS
- DIRECTORS
- HEALTHCARE PROFESSIONALS
- PRODUCT DEVELOPERS
- REGULATORY SPECIALISTS
- PRINCIPAL INVESTIGATORS
- CONSULTANTS

SESSION TRACKS

- NOVEL LIVE ATTENUATED VACCINES
- CANCER VACCINES
- HIV VACCINE
- COVID-19 VACCINE R&D
- INFLUENZA & RESPIRATORY
- BACTERIAL, TB & MALARIAL VACCINES
- EMERGING & RE-EMERGING DISEASES
- BIOPROCESSING & MANUFACTURING
- CLINICAL TRIALS
- VACCINES SAFETY & EFFICACY
- IMMUNE PROFILING
- NEW VACCINE DEVELOPMENT
- VACCINE ADJUVANTS
- DNA, RNA & SUBUNIT VACCINES
- VACCINE DELIVERY SYSTEMS
- VACCINES QA & QC
- VETERINARY VACCINES
- VACCINE DESIGN



VSBOSTON23 (EVENT SCHEDULE)

CONFERENCE VENUE

BOSTON MARRIOTT NEWTON HOTEL 2345 COMMONWEALTH AVENUE NEWTON, MA 02466, USA

MONDAY

MAY

- 08:00 Inaugural Ceremony
- 08:10 Keynote Talks I
- 09:00 **Pre-Recorded Presentation**
- 09:30 Refreshment break I
- 09:40 Session Talks I
- 12:40 Lunch

MAY




20:00 **GALA NETWORKING DINNER**



13:30	Session Talks - II
16:30	Refreshment break – II
16:40	Session Talks - II (Cont.)
17:40	Poster Presentation

MAY



- 08:00 Keynote Talks II
- 09:40 Refreshment break I
- 09:50 Session Talks III
- 12:50 Lunch
- 13:40Session Talks III (Cont.)
- 14:40 Session Talks IV
- 16:40 Refreshment break II
- 16:50 Session Talks IV (Cont.)

MAY WEDNESDAY

08:10 Keynote Talks - III
09:00 Session Talks - V
10:00 Refreshment break - I
10:10 Session Talks - V (Cont.)
11:40 Session Talks - VI
13:10 Lunch

MAY	DAY 1 SCHEDULE
8:00-8:10	Monday INAUGURAL CEREMONY
	KEYNOTE TALKS - I
8:10-9:00	DON J. DIAMOND Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA Title: Development of CMV-MVA-Triplex vaccine for reduction of cytomegalovirus complication post-transplantation
9:00-9:30	LUIGI BUONAGURO (PRE-RECORDED PRESENTATION) Director, Innovative Immunological Models Unit, National Cancer Institute - IRCCS "Pascale" Title: Viral antigens as cancer vaccines
	REFRESHMENT BREAK - I (10 MINS)
	SESSION TALKS - I

CANCER VACCINES | NOVEL LIVE ATTENUATED VACCINES | HIV VACCINES

WIM VAN CRIEKINGE 9:40-10:10

Chief Scientific Officer, myNEO, USA

Title: Exploring and validating clinical validity of lncRNAs as a novel source of immunogenic targets for immunotherapy

10:10-10:40 **ELI GILBOA**

Dodson Professor for Microbiology & Immunology, University of Miami, USA

Title: Vaccination against a common set of neoantigens induced in tumors and pathogen infected cells

10:40-11:10 **ADAM E. SNOOK**

Associate Professor, Department of Pharmacology, Physiology, & Cancer **Biology**, Thomas Jefferson University, USA Title: Adjuvant vaccines to prevent GI cancer recurrence

11:10-11:40 **JUDITH ALAMARES-SAPUAY**

Senior Scientist, Global Immunology, Vaccines R&D, Sanofi, USA Title: Optimization and characterization of a live attenuated respiratory syncytial virus vaccine candidate

PIROUZ DAFTARIAN 11:40-12:10

Director of Scientific Engagement, Crown Bioscience, MBLI, and JSR Life Sciences, USA Title: Today's metrics of immunogenicity of cancer vaccines

12:10-12:40

MARTIN MOORE

Founder & Chief Scientific Officer, Meissa Vaccines, USA Title: Safety and immunogenicity of a live, attenuated RSV vaccine in RSV-naive children 6 to 36 months of age

LUNCH BREAK (50 MINS)

SESSION TALKS - II

DNA, RNA & SUBUNIT VACCINES | COVID-19 VACCINE R&D | NEW VACCINE DEVELOPMENT-I

13:30-14:00 SARITA K. ACHARYA

Principal Scientist, Global Biologics, United States Pharmacopiea, USA Title: Ensuring quality and safety of mRNA vaccines today & tomorrow

14:00-14:30 **KUN ZHOU**

Project Lead, GeneLeap Biotech, USA Title: A Novel mRNA-based therapeutic vaccine to target HPV16associated cervical lesions

14:30-15:00 **VIRA BITKO**

Vice President, Head of Vaccine Therapeutics, RVAC Medicines, USA Title: Development of RSV mRNA vaccine

15:00-15:30 **DON J. DIAMOND**

Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, USA representing GeoVax, USA

Title: Assessment of Geo-CM04S1 for prevention of COVID-19 in immunocompromised cell therapy patients; An open-label safety study

15:30-16:00

FENG XUAN

Co-founder, President & CTO, Spear Bio, USA

Title: A novel ultrasensitive cell-free SARS-CoV-2 neutralizing antibody assay for measuring humoral immune response of vaccine with high lab-to-lab consistency

16:00-16:30 **URMI CHHEDA**

Associate Scientist, GreenLight Biosciences, USA Title: Stability of mRNA LNP

REFRESHMENT BREAK - II (10 MINS)

16:40-17:10 **THORSTEN VOGEL**

Director, Technology & External Innovation, Global Immunology, Research, Sanofi, USA

Title: Proof of concept of multivalent/octavalent vaccine platforms in naïve ferrets to deliver Influenza HA and NA antigens together for improved immunogenicity against NA compared to standard Influenza vaccines

17:10-17:40 **MITHILA FERDOUS**

Senior Scientist, Department of Global Immunology, Sanofi, USA

Title: Evaluation of novel influenza mRNA vaccine supplemented with neuraminidase to improve protection against disease in ferrets

POSTER PRESENTATION (30 MINS)

DAY 2 SCHEDULE

Tuesday KEYNOTE TALKS - II

8:00-8:50

MAY

SABINE HAUCK

EVP Corporate Development, Leukocare AG, Germany

Title: Next generation in formulation development for vaccines

8:50-9:40 WILLIAM R. JACOBS JR.

TBA

Leo & Julia Forchheimer Chair, Microbiology and Immunology, Albert Einstein College of Medicine, USA

Title: Current progress towards a new tuberculosis vaccine

REFRESHMENT BREAK - I (10 MINS)

SESSION TALKS - III

IMMUNE PROFILING | VACCINE DESIGN | NEW VACCINE DEVELOPMENT-II

9:50-10:20

	TBA
	Title: TBA
10:20-10:50	AARON ESSER-KAHN
	Associate Professor, Pritzker School of Molecular Engineering, University of Chicago, USA
	Title: The challenge of making every vaccine safer and more effective: Engineering signal processing of innate immune cells
10:50-11:20	MAGDALENA TARY-LEHMANN
	Chief Scientific Officer, Cellular Technology Limited, USA
	Title: Immunogenicity assessment in support of gene therapy programs - use of ELISPOT
11:20-11:50	DE-CHU CHRISTOPHER TANG
	Chief Executive Officer, VaxDome, USA
	Title: Broad-spectrum vaccine-antiviral hybrid without constraints imposed by viral mutations
11:50-12:20	JOSEPH G. JOYCE
	Distinguished Scientist, Vaccine Process R&D (VPRD), Merck, USA
	Title: Development and clinical assessment of a novel 21-valent pneumococcal conjugate vaccine (V116)
	THIS PROGRAM IS SUBJECT TO CHANGE

12:20-12:50VICTOR BRONSHTEIN

President & CSO, Universal Stabilization Technologies (Vitrilife), USA Title: VitriLife® technology platform for industrial production and mucosal delivery of thermostable vaccines and other biopharmaceuticals

LUNCH BREAK (50 MINS)

13:40-14:10MARK EMALFARB

President & CEO, Dyadic International, USA

Title: Transforming manufacturing & closing the technology gap in least developed countries

14:10-14:40 KEVIN P. KILLEEN

Chief Scientific Officer, Matrivax, USA Title: MVX01: A global, serotype-independent, pneumococcal protein fusion vaccine candidate

SESSION TALKS - IV

CLINICAL TRIALS | VACCINE DELIVERY SYSTEMS | BIOPROCESSING & MANUFACTURING

14:40-15:10ROBERT DILLMAN

Chief Medical Officer, AIVITA Biomedical, USA

Title: Clinical progress with personal dendritic cell vaccines for cancer and covid infection

15:10-15:40VANESSA ELHARRAR

Vice President, Vaccines Business Strategy Lead, PPD, USA

Title: Key considerations for vaccine development in special populations (elderly, pregnant, immuno-compromised, pediatrics)

15:40-16:10 MICHAEL SUMNER

Chief Medical Officer, Inovio, USA

Title: Advancing DNA medicines: Clinical updates on Ebola and recurrent respiratory papillomatosis candidates

16:10-16:40SHAHIN GHARAKHANIAN

MD Consulting LLC, CIC: Cambridge Innovation Center, USA

Title: P28GST, a therapeutic vaccine for the treatment of chronic inflammatory diseases. Data supporting clinical indication and case study

REFRESHMENT BREAK - II (10 MINS)

16:50-17:20

LYNDA TUSSEY

Chief Development Officer, Vaxess Technologies, USA Title: Phase 1 clinical evaluation of VX-103: A sustained-release, patchbased influenza vaccine delivered on the MIMIXTM platform

17:20-17:50 JAMES Z. DENG Associate Principal Scientist, Vaccine Analytical R&D, Merck, USA Title: Analytical strategies for characterization of multi-valent pneumococcal conjugate vaccine 17:50-18:20 MIC MCGOLDRICK Associate Director Global CMC Policy, Merck&Co., Inc. on behalf of IFPMA, USA Title: Accelerating access to vaccines – Next steps beyond the pandemic 18:20-18:50 MATTHEW A. COLEMAN Staff Scientist, Lawrence Livermore National Laboratory, USA Title: Co-translational cell-free expression of Chlamydial membrane bound proteins for antigen discovery and application

DAY 3 SCHEDULE MAY Wednesday

KEYNOTE SESSION - III

8:10-9:00

ADRIAN V. S. HILL

Director, The Jenner Institute, University of Oxford, UK

Title: Phase 3 progress with a high efficacy malaria vaccine

SESSION TALKS - V

INFLUENZA & RESPIRATORY | BACTERIAL, TB & MALARIAL VACCINES | VETERINARY VACCINES

9:00-9:30

TRUDY MORRISON

Professor, University of Massachusetts Chan Medical School, USA

Title: The Respiratory syncytial virus G protein enhances the immune responses to the RSV F protein in an enveloped virus-like particle vaccine candidate

9:30-10:00

CHRISTOPHER P. LOCHER

Co-Founder & CEO, Versatope Therapeutics, USA

Title: Structure and function of a broad-strain influenza vaccine using nano-vesicles

REFRESHMENT BREAK - I (10 MINS)

10:10-10:40

JUN LIN

Professor of Infectious Disease, The University of Tennessee, USA

Title: Enterobactin-based immune intervention against Gram-negative pathogens

10:40-11:10 SELVAKUMAR SUBBIAN

Principal Investigator, Public Health Research Institute, New Jersey Medical School, **Rutgers University, USA**

Title: Immune response of BCG vaccination is shaped by the nature and infectious inoculum of pathogenic Mycobacterium tuberculosis

CHINNASWAMY JAGANNATH 11:10-11:40

Professor, Pathology & Genomic Medicine, Houston Methodist Research Institute & Weill Cornell Medical College, USA

Title: New generation adenoviral and mRNA-based tuberculosis vaccines

SESSION TALKS - VI

VACCINE ADJUVANTS EMERGING & RE-EMERGING DISEASES

11:40-12:10 LEI JIN

Associate Professor of Medicine, University of Florida, USA Title: Mucosal vaccine for the aged: Decode cyclic dinucleotides adjuvanticity

12:10-12:40 **JOSEPH M. VINETZ**

Professor of Medicine (Infectious Diseases), Yale University School of Medicine, USA Title: Exploiting bacterial genomics to delineate mechanisms of pathogenesis, enabling vaccine development for an emerging/reemerging zoonotic infectious disease

12:40-13:10 **TBA** TBA Title: TBA

LUNCH BREAK (60 MINS)

WE HAVE SESSION AND POSTER SLOTS AVAILABLE

To present your work at VSBOSTON, contact: priyanka.mebsc.events

POSTER SESSION

POSTER-01ANDREW J. RENNEKAMP

Medical Science Liaison, CSL Seqirus, USA

Title: Real world study of adjuvanted influenza vaccine in preventing cardio-respiratory related hospitalizations in the elderly during the 2019-2020 U.S. influenza season

POSTER-02 MARK EMALFARB

President & CEO, Dyadic International, USA Title: Development of the thermophilic filamentous fungus <u>Thermothelomyces heterothallica</u> C1 into a prominent human and animal vaccines production platform

POSTER-03 ABEL E. VASQUEZ

TBA

Title: The surface immunogenic recombinant protein from Streptococcus agalactiae is a potential new vaccine adjuvant

POSTER-04KAROLYNE WARNY

Senior Research Associate, Global Immunology, Sanofi, USA Title: Preclinical benefit of recombinant NA addition to HA-based protein vaccine reduced disease severity in a ferret challenge model

WE HAVE SESSION AND POSTER SLOTS AVAILABLE To present your work at VSBOSTON, contact: priyanka.m@bsc.events

Thank youSEE YOU AT VSBOSTON23